CWR22: The First Human Prostate Cancer Xenograft with Strongly Androgen-dependent and Relapsed Strains Both in Vivo and in Soft Agar
作者： Joseph M. Giaconia , Paul H. Gumerlock , Theresa P. Pretlow , Thomas G. Pretlow , Saeid B. Amini
DOI:
关键词:
摘要: Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months years. Only two cancer xenografts, LNCaP and PC-346, have been reported be responsive subsequently. Both these tumors shrink slightly, if at all, less than 5 weeks withdrawal. After withdrawal, the human primary xenograft CWR22 regresses markedly, prostate-specific antigen (PSA) falls up 3000-fold in blood mice. PSA usually returns normal. In some animals, tumor relapses is then designated CWR22R. starts rise approximately 2-7 months, begins grow 3-10 castration. Animals with need euthanized because large 6-12 transplantation CWR22. Androgen withdrawal prolongs life 3-4-fold.
aacrjournals.org
elsevier.com
researchgate.net 参考文章(10)
P. Krasovich, S. E. Fry, T. H. Stanisic, R. N. Buick, J. M. Trent, S. E. Salmon, Development of an agar-methyl cellulose clonogenic assay for cells in transitional cell carcinoma of the human bladder Cancer Research. ,vol. 39, pp. 5051- 5056 ,(1979)
Thomas G. Pretlow, Gregory S. Ogrinc, Saeid B. Amini, Carrie M. Delmoro, Kay F. Molkentin, James K. V. Willson, Theresa P. Pretlow, A better defined medium for human prostate cancer cells. In Vitro Cellular & Developmental Biology – Animal. ,vol. 29, pp. 528- 530 ,(1993) , 10.1007/BF02634145
A. Hamburger, S. Salmon, Primary bioassay of human tumor stem cells Science. ,vol. 197, pp. 461- 463 ,(1981) , 10.1126/SCIENCE.560061
Arnon Rosenthal, Patricia B. Lindquist, Timothy S. Bringman, David V. Goeddel, Rik Derynck, Expression in rat fibroblasts of a human transforming growth factor-α cDNA results in transformation Cell. ,vol. 46, pp. 301- 309 ,(1986) , 10.1016/0092-8674(86)90747-6
Thomas G. Pretlow, Theresa P. Pretlow, Bin Yang, Charlotte S. Kaetzel, Carrie M. Delmoro, Sheryl M. Kamis, Donald R. Bodner, Elroy Kursh, Martin I. Resnick, Edwin L. Bradley, Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia International Journal of Cancer. ,vol. 49, pp. 645- 649 ,(1991) , 10.1002/IJC.2910490503
X. Zhao, G. J. van Steenbrugge, F. H. Schröder, Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor Urological Research. ,vol. 20, pp. 193- 197 ,(1992) , 10.1007/BF00299716
Andrew C. Von Eschenbach, Martin E. Gleave, Leland W K Chung, Hsi Chin Wu, Jer Tsong Hsieh, Serum Prostate Specific Antigen Levels in Mice Bearing Human Prostate LNCaP Tumors Are Determined by Tumor Volume and Endocrine and Growth Factors Cancer Research. ,vol. 52, pp. 1598- 1605 ,(1992)
T. G. Pretlow, S. R. Wolman, M. A. Micale, R. J. Pelley, E. D. Kursh, M. I. Resnick, D. R. Bodner, J. W. Jacobberger, C. M. Delmoro, J. M. Giaconia, T. P. Pretlow, Xenografts of Primary Human Prostatic Carcinoma Journal of the National Cancer Institute. ,vol. 85, pp. 394- 398 ,(1993) , 10.1093/JNCI/85.5.394
Schröder Fh, Endocrine therapy: where do we stand and where are we going? Cancer surveys. ,vol. 11, pp. 177- 194 ,(1991)
Resnick Mi, Grayhack Jt, Treatment of stage IV carcinoma of the prostate. Urologic Clinics of North America. ,vol. 2, pp. 141- ,(1975)